Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
Belcaid Z, Berrevoets C, Choi J, van Beelen E, Stavrakaki E, Pierson T, Kloezeman J, Routkevitch D, van der Kaaij M, van der Ploeg A, Mathios D, Sleijfer S, Dirven C, Lim M, Debets R, Lamfers MLM.
Belcaid Z, et al. Among authors: sleijfer s.
Neurooncol Adv. 2020 Feb 3;2(1):vdaa011. doi: 10.1093/noajnl/vdaa011. eCollection 2020 Jan-Dec.
Neurooncol Adv. 2020.
PMID: 32642679
Free PMC article.